Taiho Oncology
Subsidiary of Otsuka Holdings (4578)
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Small molecule | Acute Myeloid LeukemiaMyelodysplastic Syndromes |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Decitabine/cedazuridine (Inqovi)Phase 2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Est. primary completion 2027-12-31 · NCT04093570 · CT.gov ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
US, FDA · FDA · Source ↗
Recent
28 April 2026Filing acceptedZipalertinibFDA accepts NDA for zipalertinib (previously treated EGFR ex20ins NSCLC)
US, FDA · Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics · Source ↗
Financial reports
No financial reports recorded.